As prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understanding the similarities and differences between ADAD and "sporadic" late-onset AD (LOAD) is critical to determine generalizability of findings between these cohorts. Cognitive trajectories of ADAD mutation carriers (MCs) and autopsy-confirmed LOAD individuals were compared to address this question. Longitudinal rates of change on cognitive measures were compared in ADAD MCs (n = 310) and autopsy-confirmed LOAD participants (n = 163) before and after symptom onset (estimated/observed). LOAD participants declined more rapidly in the presymptomatic (preclinical) period and performed more poorly at symptom onset than ADAD participants on a cogniti...
Abstract Objectives Early‐ and late‐onset Alzheimer's disease (EOAD and LOAD) share the same neuropa...
Ministry of Health and Welfare, Republic of KoreaEarly-onset Alzheimer's disease (EOAD) has been...
Objective: To assess the onset, sequence and rate of progression of comprehensive biomarker and clin...
As prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understa...
Abstract Background Although few studies have shown that risk factors for Alzheimer’s disease (AD) a...
Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (A...
To compare the rate of cognitive and functional decline in dysexecutive, typical and amnestic subgro...
BackgroundThe overarching goal of the Longitudinal Early- onset Alzheimer Disease study (LEADS) is ...
To compare the rate of cognitive and functional decline in dysexecutive, typical and amnestic subgro...
Early-onset Alzheimer's disease (EOAD) has been shown to progress more rapidly than late-onset Alzhe...
International audienceNeuroimaging biomarkers differ between patients with early-onset Alzheimer's d...
Autosomal dominant Alzheimers disease (ADAD) is genetically determined, but variability in age of sy...
The extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the...
International audienceAbstract Background Lack of awareness of cognitive decline (ACD) is common in ...
ImportanceAutosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 speci...
Abstract Objectives Early‐ and late‐onset Alzheimer's disease (EOAD and LOAD) share the same neuropa...
Ministry of Health and Welfare, Republic of KoreaEarly-onset Alzheimer's disease (EOAD) has been...
Objective: To assess the onset, sequence and rate of progression of comprehensive biomarker and clin...
As prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understa...
Abstract Background Although few studies have shown that risk factors for Alzheimer’s disease (AD) a...
Defining a signature of cortical regions of interest preferentially affected by Alzheimer disease (A...
To compare the rate of cognitive and functional decline in dysexecutive, typical and amnestic subgro...
BackgroundThe overarching goal of the Longitudinal Early- onset Alzheimer Disease study (LEADS) is ...
To compare the rate of cognitive and functional decline in dysexecutive, typical and amnestic subgro...
Early-onset Alzheimer's disease (EOAD) has been shown to progress more rapidly than late-onset Alzhe...
International audienceNeuroimaging biomarkers differ between patients with early-onset Alzheimer's d...
Autosomal dominant Alzheimers disease (ADAD) is genetically determined, but variability in age of sy...
The extent to which the pathophysiology of autosomal dominant Alzheimer's disease corresponds to the...
International audienceAbstract Background Lack of awareness of cognitive decline (ACD) is common in ...
ImportanceAutosomal dominant Alzheimer disease (ADAD) is caused by rare genetic mutations in 3 speci...
Abstract Objectives Early‐ and late‐onset Alzheimer's disease (EOAD and LOAD) share the same neuropa...
Ministry of Health and Welfare, Republic of KoreaEarly-onset Alzheimer's disease (EOAD) has been...
Objective: To assess the onset, sequence and rate of progression of comprehensive biomarker and clin...